A case of indolent systemic mastocytosis responding to treatment with Avapritinib

Key Clinical MessageLow dose Avapritinib is a new medication that is a potential treatment option not just for advanced systemic mastocytosis, but also for the indolent form.

Source: Clinical Case Reports - February 24, 2024 Category: General Medicine Authors: Terrence Sun, Marin Xavier Tags: CASE REPORT Source Type: research